Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study
- PMID: 33348045
- DOI: 10.1016/j.cgh.2020.12.022
Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study
Abstract
Background & aims: An international expert panel proposed a new definition for metabolic dysfunction-associated fatty liver disease (MAFLD) as a name change from nonalcoholic fatty liver disease (NAFLD). The clinical impact of this change on the assessment of cardiovascular disease (CVD) risk is yet unknown. We evaluated the prevalence of fatty liver disease (FLD) and the associated CVD risk using each of these definitions.
Methods: From a nationwide health screening database, we included 9,584,399 participants (48.5% male) aged 40-64 years between 2009 and 2010. Participants were categorized by presence of NAFLD and MAFLD, separately, and by the combination of the 2 definitions-Neither-FLD, NAFLD-only, MAFLD-only, or Both-FLD. The primary outcome was a composite CVD event, including myocardial infarction, ischemic stroke, heart failure, or CVD-related death.
Results: The prevalence of NAFLD and MAFLD was 28.0% and 37.3%, respectively. After excluding those with prior CVD, 8,962,813 participants were followed for a median of 10.1 years. NAFLD and MAFLD were each associated with significantly higher risk for CVD events. When the Neither-FLD group was the reference, multivariable-adjusted hazard ratios (95% confidence interval) for CVD events were 1.09 (1.03-1.15) in the NAFLD-only group, 1.43 (1.41-1.45) in the MAFLD-only group, and 1.56 (1.54-1.58) in the Both-FLD group.
Conclusions: A considerable proportion of middle-aged Korean adults have MAFLD without satisfying the former definition of NAFLD. The change from NAFLD to MAFLD criteria may identify a greater number of individuals with metabolically complicated fatty liver and increased risk for CVD.
Keywords: Cardiovascular Diseases; Metabolic Dysfunction-Associated Fatty Liver Disease; Nonalcoholic Fatty Liver Disease; Prevalence; Risk Factors.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
MAFLD and Cardiovascular Events: What Does the Evidence Show?Clin Gastroenterol Hepatol. 2021 Oct;19(10):2025-2028. doi: 10.1016/j.cgh.2021.02.027. Epub 2021 Feb 18. Clin Gastroenterol Hepatol. 2021. PMID: 33610759 No abstract available.
Similar articles
-
Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.Clin Transl Gastroenterol. 2022 Jan 12;13(1):e00435. doi: 10.14309/ctg.0000000000000435. Clin Transl Gastroenterol. 2022. PMID: 35080508 Free PMC article.
-
Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.J Gastroenterol. 2021 Nov;56(11):1022-1032. doi: 10.1007/s00535-021-01828-6. Epub 2021 Oct 3. J Gastroenterol. 2021. PMID: 34601620 Free PMC article.
-
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.Diabetes Metab. 2022 Jul;48(4):101344. doi: 10.1016/j.diabet.2022.101344. Epub 2022 Mar 25. Diabetes Metab. 2022. PMID: 35346856
-
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.Eur J Clin Invest. 2021 Jul;51(7):e13519. doi: 10.1111/eci.13519. Epub 2021 Mar 2. Eur J Clin Invest. 2021. PMID: 33583033 Review.
-
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?Clin Mol Hepatol. 2021 Apr;27(2):257-269. doi: 10.3350/cmh.2021.0067. Epub 2021 Mar 22. Clin Mol Hepatol. 2021. PMID: 33751877 Free PMC article. Review.
Cited by
-
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD.Rev Cardiovasc Med. 2023 May 31;24(6):157. doi: 10.31083/j.rcm2406157. eCollection 2023 Jun. Rev Cardiovasc Med. 2023. PMID: 39077530 Free PMC article. Review.
-
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia.Rev Cardiovasc Med. 2023 Jun 14;24(6):173. doi: 10.31083/j.rcm2406173. eCollection 2023 Jun. Rev Cardiovasc Med. 2023. PMID: 39077515 Free PMC article. Review.
-
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.Nutrients. 2024 Jul 11;16(14):2220. doi: 10.3390/nu16142220. Nutrients. 2024. PMID: 39064665 Free PMC article. Review.
-
Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality.Hepatol Commun. 2024 Jul 22;8(8):e0490. doi: 10.1097/HC9.0000000000000490. eCollection 2024 Aug 1. Hepatol Commun. 2024. PMID: 39037383 Free PMC article.
-
Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study.Sci Rep. 2024 Jun 3;14(1):12663. doi: 10.1038/s41598-024-63453-6. Sci Rep. 2024. PMID: 38830939 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical